Degarelix is a synthetic peptide used to treat advanced prostate cancer, and it represents a different approach to hormone therapy than the GnRH agonist drugs, like leuprolide, that have been standard for decades.
What It Is
Degarelix is a synthetic decapeptide, a 10-amino-acid peptide, that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist. It is sold under the brand name Firmagon and given by subcutaneous injection.
How It Works
GnRH normally signals the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulate the testes to produce testosterone. Prostate cancer cells are frequently stimulated to grow by testosterone, so lowering testosterone to castration levels is a standard treatment strategy. Older GnRH agonist drugs, including leuprolide and goserelin, work by overstimulating the GnRH receptor until the pituitary becomes desensitized and testosterone production falls, but they cause an initial testosterone surge, or "flare," in the first one to two weeks of treatment, which can temporarily worsen cancer symptoms. Degarelix, as a direct receptor antagonist, blocks the GnRH receptor immediately rather than overstimulating it, producing a rapid drop in LH, FSH, and testosterone without that initial surge.
Regulatory Status
Degarelix received FDA approval in 2008 for the treatment of advanced prostate cancer. It remains an approved option, typically used when avoiding the testosterone flare associated with GnRH agonists is clinically important, such as in men with significant bone metastases or urinary obstruction where a temporary symptom flare carries real risk.
What the Research Shows
Degarelix's approval was supported by clinical trials demonstrating that it achieves and maintains testosterone suppression to castration levels, defined as below 50 ng/dL, without the initial surge seen with GnRH agonists, and that this suppression is sustained with monthly dosing. Comparative studies have examined differences in cardiovascular safety signals between GnRH antagonists and agonists, an active area of ongoing research in prostate cancer treatment more broadly.
Safety Considerations
Injection site reactions, including pain, redness, and swelling, are common with degarelix and tend to be more frequent than with GnRH agonist injections. Because profound testosterone suppression carries class-wide risks, degarelix labeling includes monitoring considerations for QT interval prolongation, bone density loss, and metabolic changes such as weight gain and altered glucose and lipid levels. As with other hormone therapies for prostate cancer, degarelix is used under oncology supervision, and it is not used for any condition outside prostate cancer treatment.
Dosing and Administration
Degarelix is given as a subcutaneous injection into the abdominal area, typically starting with a higher loading dose followed by monthly maintenance injections. Because it must be mixed and administered correctly to maintain consistent testosterone suppression, it's given under medical supervision rather than self-administered at home, and patients are monitored periodically with testosterone and prostate-specific antigen (PSA) blood tests to confirm the treatment is working as expected.
The Bottom Line
Degarelix illustrates how peptide drugs can achieve the same ultimate goal, testosterone suppression for prostate cancer, through a meaningfully different mechanism than older alternatives, with a clinical tradeoff between avoiding the agonist flare effect and accepting a different injection-site side effect profile. It remains one of several FDA-approved peptide options physicians choose between based on an individual patient's cancer stage and other health factors.